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Summary 
 
Background The incidence of obscure gastrointestinal bleeding, which originates from the small bowel and is mainly 
associated with the use of aspirin and non-steroidal anti-infl ammatory drugs (NSAIDs), is rising. We assessed the 
efficacy and safety of misoprostol for the treatment of small bowel ulcers and erosions in patients taking low-dose 
aspirin or NSAIDs with obscure gastrointestinal bleeding. 
Methods In this randomised, double-blind, placebo-controlled, phase 3 trial, we recruited patients (aged >18 years) 
with small bowel ulcers who were taking low-dose aspirin, NSAIDs, or both for a minimum of 4 weeks, at University 
Hospital Crosshouse (Kilmarnock, UK). Eligible patients had evidence of obscure gastrointestinal bleeding 
(iron deficiency anaemia, a decrease in haemoglobin concentration of >20 × 10³ mg/L, or positive faecal occult blood 
test) and normal upper endoscopy and colonoscopy. Patients were randomly assigned (1:1) using an interactive voice 
response system to receive 200 μg oral misoprostol or placebo four times daily for 8 weeks. Patients, investigators, 
and assessors were masked to treatment allocation. The primary endpoint was the complete healing of small bowel 
ulcers and erosions, assessed by video capsule endoscopy after 8 weeks of treatment. Primary analysis was by modified 
intention to treat, which included all randomised patients who received at least one dose of study treatment. Safety was 
assessed in the same population. The trial is registered with ClinicalTrials.gov, number NCT02202967. 
Findings Between Jan 7, 2016, and Oct 11, 2017, we randomly allocated 104 eligible patients: 52 to receive misoprostol 
and 52 to receive placebo. Two patients allocated to misoprostol were later found to meet one of the exclusion criteria, 
thus 50 randomly assigned patients in the misoprostol group and 52 patients in the placebo group received at least one 
dose of study treatment. Complete healing of small bowel ulcers and erosions was noted at week 8 in 27 (54%) of 50 
patients in the misoprostol group and nine (17%) of 52 patients in the placebo group (percentage difference 36·7%, 95% 
CI 19·5–53·9; p=0·0002). Adverse events occurred in 23 (46%) of 50 patients in the misoprostol group and 22 (42%) of 52 
patients in the placebo group. The most common adverse events were abdominal pain (ten [20%] in the misoprostol 
group vs 13 [25%] in the placebo group), nausea or vomiting (nine [18%] vs seven [13%]), and diarrhoea (11 [22%] vs six 
[12%]). Four (8%) of 50 patients in the misoprostol group had severe adverse events, compared with none in the placebo 
group. No serious adverse events were reported. 
Interpretation Misoprostol is effective for the treatment of small bowel ulcers and erosions in patients using low-dose 
aspirin and NSAIDs. Misoprostol might represent a pharmacological treatment option for lesions causing obscure 
gastrointestinal bleeding that is associated with aspirin and NSAIDs, but its use should be balanced against the risk 
of side-effects. 
 
Funding National Health Service (NHS) Greater Glasgow and Clyde and NHS Ayrshire and Arran. 
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Introduction 
 
Bleeding in the gastrointestinal tract is generally classified according to anatomical location—ie, upper gastrointestinal 
bleeding (ie, proximal to the ligament of Treitz) or lower gastrointestinal bleeding.1–3 The incidence of upper 
gastrointestinal bleeding has been declining since 2007, largely due to the use of proton-pump inhibitors and the 
eradication of Helicobacter pylori infection, and the diagnosis and management of obscure gastrointestinal bleeding, which 
is distinct from upper and lower gastrointestinal bleeding, has become a focus of research.3–6 This condition is common in 
people with iron deficiency anaemia or overt or occult gastrointestinal bleeding, in whom no potential source of bleeding is 
found on oesophagogastroduodenoscopy or colonoscopy.3–6 We previously found that the annual incidence of occult or 
obscure gastrointestinal bleeding among individuals in southwest Scotland increased from 243·1 per 100 000 individuals in 
2007, to 292·8 per 100 000 individuals in 2012, and the corresponding incidence of upper gastrointestinal bleeding 
decreased from 140·1 per 100 000 individuals in 2007, to 88·0 per 100 000 individuals in 2012.6 These changes were 
associated with an increase in the number of prescriptions of non-steroidal anti-inflammatory drugs (NSAIDs), aspirin, and 
proton-pump inhibitors between 2007 and 2012.6 Obscure gastrointestinal bleeding mainly originates from the small 
bowel, and its incidence has been rising, which might be explained by the widespread use of low-dose aspirin and NSAIDs.3–
6 The diagnosis of small bowel ulcers in patients taking these drugs has been facilitated by the introduction of video capsule 
endoscopy.7–9 Small bowel ulcers develop as a result of the suppression of mucosal prostaglandin synthesis by aspirin or 
NSAIDs,7–9 and because of the alkaline environment of the small bowel, these ulcers do not respond to acid inhibitors.7 A 
pilot study10 found that small bowel mucosal lesions associated with aspirin use healed following treatment with 
misoprostol (a prostaglandin analogue) in four of seven patients. Preliminary data11 have shown that misoprostol was more 
effective than placebo for the treatment of small bowel ulcers associated with aspirin use. Additionally, a previous 
retrospective short report12 of a study including a small number of patients suggested that anaemia improved in 11 patients 
with NSAID-induced enteropathy given misoprostol compared with ten patients not taking misoprostol. However, these 
results have not been confirmed in prospective trials or in larger cohorts of patients.11 Moreover, little is known about the 
efficacy of misoprostol for the treatment of NSAID-associated or aspirin-associated small bowel ulcers in patients with 
obscure gastrointestinal bleeding. 
The MASTERS study was designed to compare the efficacy and safety of misoprostol for the treatment of small bowel 
ulcers in patients with obscure gastrointestinal bleeding taking low-dose aspirin or NSAIDs. 
 
 
Methods 
Study design and patients 
This randomised, double-blind, placebo-controlled phase 3 trial was done at University Hospital Crosshouse (Kilmarnock, 
UK). Eligible patients were aged 18 years or older with small bowel ulcers who had been taking low-dose aspirin (75–325 
mg per day), NSAIDs, or both for a minimum of 4 weeks. Patients had to have evidence of obscure gastrointestinal bleeding 
(positive faecal occult blood test within the previous 3 months, iron deficiency anaemia [ ferritin <100 μg/L] and a 
haemoglobin concentration of 70–120 × 10³ mg/L [women] or 70–130 × 10³ mg/L [men], or a decrease in haemoglobin 
concentration of 20 × 10³ mg/L or more within 3 months of screening). Patients also had to have no evidence of potential 
or actively bleeding lesions on upper gastrointestinal endoscopy or colonoscopy. Patients were excluded if they had 
incomplete endoscopy or colonoscopy results, unstable systemic disease at the time of randomisation, upper 
gastrointestinal lesions (ie, oesophageal varices, oesophageal stricture, oesophageal or gastric neoplasms, pyloric stenosis, 
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peptic ulcers, or vascular malformations), colonic disorders (neoplasms or adenomatous polyps >5 mm, inflammatory 
bowel disease, vascular mal formations, or actively bleeding diverticular disease), suspected or confi rmed malignancy, 
or hypotension (systolic blood pressure <100 mm Hg). Patients who required continuous concomitant therapy with high-
dose steroids (>7·5 mg prednisolone daily), cytotoxic drugs, any anticoagulants, or antiplatelet drugs (with the exception of 
aspirin), high-dose proton-pump inhibitors or H_ receptor antagonists, or magnesiumcontaining antacids) were also 
excluded, as were women planning pregnancy, pregnant women, and women of childbearing potential not using two 
contraceptive methods (one of which had to be highly effective). Full exclusion criteria can be found in the appendix (pp 
21–23). Individuals taking iron supplements were also excluded; however, for pragmatic reasons, the use of acid inhibitors 
was permitted and taken note of in the final analysis, because this was considered unlikely to result in healing of small 
bowel ulcers.7 The trial was approved by the West of Scotland Research Ethics Committee (reference number 
14/WS/1084). All patients provided written informed consent. The study protocol is available in the appendix (pp 7–45). 
 
Randomisation and masking 
Patients were enrolled by research staff at University Hospital Crosshouse (Kilmarnock, UK). Randomisation was done at a 
central randomisation facility based at the Robertson Centre for Biostatistics (Glasgow, UK). Patients were randomly 
assigned (1:1) to receive misoprostol or placebo using an interactive voice response system. Randomisation was computer 
generated, using a block size of six without stratification. Patients, investigators, and assessors were masked to study 
treatment. To ensure masking was maintained, misoprostol and placebo capsules were identical in shape, colour, odour, 
and taste. The study statisticians were masked to treatment allocations until all analyses programs had been validated and 
the database had been locked. 
 
 
 
Procedures 
Patients received oral 200 μg misoprostol (Pfizer, Sandwich, UK) or matching placebo four times daily for 8 weeks. We did 
clinical assessments, full blood counts, and assessed ferritin concentrations in patients at baseline, and 4 and 8 weeks after 
randomisation. Patients also had video capsule endoscopy at baseline and after 8 weeks of treatment. Capsule endoscopy 
was done using the OMOM System (Jinshan Science and Technology, Chongqing, China). Patients attended for the 
procedure after an overnight fast. To prepare the small bowel, patients were given two sachets of Picolax (Ferring 
Pharmaceuticals, West Drayton, UK) on the day before the procedure. The small bowel mucosal findings were reported as 
previously described.9 Mucosal breaks (ie, ulcers or erosions) were defined as discrete lesions with central pallor and 
surrounding hyperaemia and loss of villi.9 Ulcers were arbitrarily defi ned as mucosal breaks measuring at least one-eighth 
of the cross-sectional view of the small bowel mucosa or extending between two adjacent folds. Smaller breaks were 
defined as erosions. These definitions were used because the depth of lesions is often difficult to assess as a result of the 
angle of the capsule endoscopy image.9 Baseline and post-treatment capsule endoscopy findings were assessed by two 
adjudicators who were blinded to treatment allocation and had standardised their descriptions before the study. Any 
discrepancies were resolved by consensus. 
 
Outcomes 
The primary endpoint was the complete healing of small bowel ulcers or erosions, as assessed by video capsule endoscopy 
after 8 weeks of treatment. The secondary endpoints were change in the number of small bowel mucosal erosions, and 
change in blood haemoglobin concentration after 4 and 8 weeks of treatment. Prespecified per-protocol analyses were 
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done for the primary and safety endpoints. Subgroup analysis of haemoglobin concentrations at 4 weeks and 8 weeks was 
done in patients with and without anaemia at baseline. Post-hoc exploratory endpoints were complete healing of small 
bowel mucosal ulcers and erosions, change in the number of small bowel mucosal ulcers, and complete case analysis of 
complete healing of small bowel mucosal ulcers and erosions, change in the number of small bowel mucosal ulcers, and 
change in the number of small bowel mucosal erosions, assessed at 8 weeks. Adverse events and safety were assessed 
using patient diaries, face-to-face interviews, and clinical and laboratory assessments done at each visit. 
 
Statistical analysis 
In the OMNIUM trial,13 in which patients were assigned to receive misoprostol at a similar dose and for a similar duration as 
in our protocol, including those who did not complete treatment, approximately 70% of NSAID-induced gastric and 
duodenal ulcers were successfully healed. On the basis of these results, we assumed a similar response rate in the 
misoprostol group in the treatment phase of this study. For the placebo group we assumed that 30% of patients would 
respond to treatment (including any patients misclassified as having completely healed lesions because lesions were 
missed). We assumed that an additional 20% of patients in each group would not have a satisfactory video capsule 
endoscopy 8 weeks after treatment. For the primary analysis, this implies treatment success rates of 56% (70% × 80%) for 
the misoprostol group and 24% (30% × 80%) for the placebo group. Thus, a sample size of 104 (52 per group) was 
calculated to provide 90% power with a two-tailed significance level of 5%. 
Up to 71% of chronic NSAID users have erosive changes in the small bowel mucosa.8 The prevalence of such lesions in 
patients taking low-dose aspirin is unknown, but we assumed that at least 40% of patients taking NSAIDs or aspirin in this 
study would have small bowel erosions or ulceration on initial video capsule endoscopy, and thus would be eligible for the 
treatment phase. We therefore aimed to screen 260 patients taking low-dose aspirin, NSAIDs, or both. Categorical data are 
presented as frequencies and percentages, and continuous data are presented as median and IQR. Randomised groups 
were compared using Fisher’s exact test for binary outcomes, and continuous outcomes were compared using the 
Wilcoxon-Mann-Whitney test. Estimated treatment differences are reported as the absolute percentage difference 
(healing outcomes), the rate ratio (number of mucosal erosions and ulcers), or the mean difference (haemoglobin 
concentrations), with 95% CIs. Rate ratios were estimated using negative binomial regression models, and mean 
differences in haemoglobin were estimated using linear regression models, adjusted for baseline haemoglobin 
concentrations. Primary analyses were by modified intention to treat, with primary outcome data analysed for all patients 
who were randomly assigned and received at least one dose of study treatment. The safety analysis was done for the same 
group. Patients who did not have video capsule endoscopy 8 weeks after treatment, or those with inadequate images, 
were assumed not to have completely healed lesions. For the secondary analyses of the numbers of mucosal ulcers and 
erosions, patients without final video capsule endoscopy data were assumed to have the same findings at follow-up as 
recorded at their baseline examination. Therefore, intention-to-treat analyses of primary and secondary endpoints used a 
last value-carried-forward method of imputation of baseline measurements to impute missing values. All other analyses 
used complete data only (ie, all patients with data for the 8 week video capsule endoscopy were included). Primary and 
secondary analyses were repeated in the per-protocol population, which included all patients who took more than 75% of 
study drug capsules, did not miss more than 7 consecutive days of treatment with study drug, and had the final endoscopic 
examination. For the secondary outcomes of the number of mucosal erosions and haemoglobin concentrations at 8 weeks, 
and post-hoc analysis of number of mucosal ulcers, multivariable regression analyses were done adjusting for the following 
baseline factors: age, sex, use of aspirin, NSAIDs, proton-pump inhibitors, and statins, number of mucosal erosions, number 
of mucosal ulcers, and haemoglobin concentration. All statistical analyses were done using SAS software (version 9.4). This 
trial is registered with ClinicalTrials.gov, number NCT02202967. 
                                                                                                                                                  A S Taha et al     6 
 
Role of the funding source 
The sponsor reviewed the protocol and regularly monitored the trial. The funder had no role in study design, data 
collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the 
data in the study and had final responsibility to submit for publication. 
 
 
 
Results 
 
Between Jan 7, 2016, and Oct 11, 2017, 232 patients were screened, of whom 104 were randomly assigned (1:1) to 
receive misoprostol (n=52) or placebo (n=52; figure). Two patients assigned to the misoprostol group were excluded 
because their blood pressure at screening was lower than permitted by the protocol, and thus 50 patients in the 
misoprostol group and 52 patients in the placebo group received the study drug and were included in the modified 
intention-to-treat analysis set. Baseline characteristics, including the number and types of comorbidity, were similar across 
the two treatment groups (table 1). 35 (70%) of 50 patients in the misoprostol group and 34 (65%) of 52 patients in the 
placebo group were taking low-dose aspirin for cardiovascular protection, and 22 (44%) and 20 (38%) patients were taking 
non-selective NSAIDs for osteoarthritis. Seven (14%) of 50 patients in the misoprostol group and two (4%) of 52 patients in 
the placebo group were taking both aspirin and NSAIDs. The types of NSAIDs used are shown in table 1. None of the 
randomised patients had obscure overt gastrointestinal bleeding. 12 patients did not complete the study because they 
were unwilling to continue (ten [20%] of 50 patients in the misoprostol group, two [4%] of 52 patients in the placebo 
group), four of whom withdrew their consent (three in the misoprostol group, one in the placebo group; figure). 27 (54%) 
of 50 patients in the misoprostol group and nine (17%) of 52 patients in the placebo group had completely healed ulcers 
and erosions at 8 weeks (percentage difference 36·7%, 95% CI 19·5–53·9; p=0·0002; table 2). Similar results were obtained 
when complete healing of ulcers and erosion were assessed separately (table 2). The median number of mucosal ulcers 
decreased between baseline and after 8 weeks of treatment in the misoprostol group, and increased during the same 
period in the placebo group (p<0·0001; table 2). Similarly, the median number of mucosal erosions decreased between 
baseline and after 8 weeks of treatment in the misoprostol group, and increased during the same period in the placebo 
group (p<0·0001). No significant differences in haemoglobin concentration were identified between baseline and 4 weeks 
after treatment, or between baseline and 8 weeks after treatment in either group (table 2). Subgroup analysis revealed no 
significant differences in haemoglobin concentrations at 4 weeks and 8 weeks of treatment in patients with and without 
anaemia at baseline (appendix p 4). Per-protocol analysis indicated that a higher proportion of patients in the misoprostol 
group had completely healed lesions than in the modified intention-to-treat analysis, and the number of patients with 
completely healed lesions was higher in the misoprostol group than the placebo group (appendix pp 2, 3). 
Treatment compliance did not differ significantly between the two groups: 38 (76%) of 50 patients in the misoprostol 
group and 47 (90%) of 52 patients in the placebo group took more than 75% of study drug capsules (p=0·065). The median 
time patients did not adhere to treatment for was 14 days (IQR 4–28) in the misoprostol group and 15 days (13·5–16·5) in 
the placebo group (p=0·93). One patient in the misoprostol group and three patients in the placebo group missed more 
than 7 consecutive days of treatment and were excluded from per-protocol analysis. 23 (46%) of 50 patients in the 
misoprostol group reported adverse events compared with 22 (42%) of 52 patients in the placebo group (table 3). 
Abdominal pain represented 14 (22%) of 65 events in the misoprostol group versus 14 (25%) of 57 events in the 
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placebo group, diarrhoea represented 13 (20%) events versus eight (14%) events, nausea or vomiting represented 13 (20%) 
events versus 11 (19%) events, and bloating, constipation, and reflux symptoms represented 25 (39%) events versus 24 
(42%) events (table 3). Severe adverse events occurred in four (8%) of 50 patients in the misoprostol group (nausea and 
vomiting and bloating [n=1], nausea or vomiting [n=1], bloating [n=2]); p=0·017 vs placebo, Fisher’s exact test). 
No serious adverse events were reported in either treatment group. Multivariable regression analysis of the number of 
mucosal ulcers or erosions showed that the treatment effect persisted after adjustment for a range of baseline covariates 
(both p<0·0001), but not haemoglobin concentration (p=0·44; appendix pp 5, 6). Patients taking aspirin at baseline had 
fewer mucosal erosions after 8 weeks of treatment than patients not taking aspirin at baseline (rate ratio [RR] 0·31, 95% CI 
0·11–0·90, p=0·030), and those taking statins had more mucosal ulcers after 8 weeks of treatment than at baseline 
(RR 1·62, 1·05–2·49, p=0·028). None of the other baseline characteristics analysed (except for baseline measures of the 
outcome being modelled) was associated with study outcomes. 
 
 
Discussion 
We have shown that misoprostol is effective for the treatment of mucosal ulcers and erosions of the small bowel in 
patients with obscure gastrointestinal bleeding taking low-dose aspirin or NSAIDs. Low-dose aspirin and NSAIDs are widely 
used for their respective anti-thrombotic and anti-inflammatory activities. These drugs are known to have damaging 
side-effects on the upper gastrointestinal tract (ie, oesophagus, stomach, and duodenum), where acid inhibition, 
particularly with proton-pump inhibitors, is known to be effective for the treatment of ulcers. As a result of effective acid-
inhibiting drugs, the incidence of upper gastrointestinal bleeding has decreased.1–3,6 By contrast, diagnosis of ulcers and 
erosions of the small bowel among individuals taking aspirin and NSAIDs has increased; these patients have few treatment 
options because prostaglandin production (rather than excess acid) is the primary driver of ulcer pathogenesis in the 
alkaline environment of the small bowel.3–11,14,15 Since aspirin and NSAIDs are known to cause ulcers by suppressing mucosal 
prostaglandin synthesis,3–11 we chose to include patients taking these drugs in our study. These factors highlight the 
importance of identifying a drug that can be used to heal small bowel ulcers in patients who take aspirin and NSAIDs. The 
preparations of aspirin and NSAID used in this study were non-enteric coated and no comparison with enteric coated 
compounds was done. 
Our intention-to-treat analyses of primary and secondary endpoints used a last-value-carried-forward method of 
imputation of baseline measurements to impute missing values, and thus included patients who had discontinued study 
treatment. Since the disease was progressive in patients in the placebo group, this imputation method, in combination 
with a higher number of discontinued patients in the misoprostol group, could have biased the results toward the null for 
these endpoints. However, the per-protocol analysis showed a small increase in the number of ulcers and erosions in the 
placebo group compared with a marked decrease in the misoprostol group. Imputation of missing data as no change would 
therefore decrease the between-group difference, thus we feel that the intention-to-treat analysis as specified is a 
conservative approach. 
Distinguishing between small bowel ulcers and erosions identified by capsule endoscopy can be difficult, which represents 
a limitation of our study.8,9 To overcome this limitation, the images were examined by two assessors who standardised their 
interpretation, and any discrepancies were resolved by consensus. Moreover, we showed that misoprostol was effective in 
healing both ulcers and erosions, regardless of their classification, when analysed separately and in combination. 
Our study has a number of additional limitations. The study was done at a single centre, most patients were 
white, and no women of childbearing age were included. Furthermore, less than half of patients taking either 
misoprostol or placebo had iron deficiency anaemia at baseline and patients with severe or unstable systemic 
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diseases were excluded. These factors might limit the generalisability of our findings and warrant further investigation. 
To the best of our knowledge, this is the largest study to date investigating the efficacy of misoprostol in this setting. Our 
findings are consistent with the results of an open-label pilot study10 and double-blind study11 investigating misoprostol in 
individuals using low-dose aspirin. In those studies, the number of patients with completely healed lesions was lower than 
that in our study, possibly because of the difference in ethnicities of the included populations (individuals from southeast 
Asia vs individuals from western Europe). However, similar to our study, haemoglobin concentrations were not found to 
increase as a result of small bowel ulcer and erosion healing,11 which might indicate that small bowel lesions were not the 
cause of gastrointestinal bleeding manifesting as iron deficiency anaemia or decreased haemoglobin concentrations. 
However, we believe that the strict inclusion and exclusion criteria used, coupled with the absence of potential sources of 
blood loss on upper endoscopy and colonoscopy, indicate that obscure gastrointestinal bleeding was most likely to be 
caused by small bowel lesions in this study and previous studies.2–11 Patients taking iron supplements, which are frequently 
given to treat obscure gastrointestinal bleeding,6 were excluded from this study and previous studies.11 Therefore, the 
intake of misoprostol for longer than 8 weeks or combined with iron supplements might result in higher haemoglobin 
concentrations than observed,11 but this needs to be confirmed. 
Our study included patients with abdominal symptoms and positive faecal occult blood tests, but normal 
haemoglobin concentrations, which might have made it difficult to identify any increases in haemoglobin 
concentrations after 8 weeks of treatment, and might be considered a limitation of our study. However, these findings 
should not diminish the clinical importance of the findings of this study. We also believe that the identification of small 
bowel ulcers is clinically significant in patients with abdominal complaints and positive faecal occult blood tests who are 
taking aspirin or NSAIDs. Clinicians might find it difficult to reassure these patients about their small bowel ulcers and 
occult bleeding solely on the basis of normal endoscopy and colonoscopy results. Patients taking aspirin or NSAIDs who 
have similar ulcers in the stomach or duodenum are normally prescribed acid inhibitors or misoprostol, regardless of the 
presence or absence of symptoms, because of the risk of serious complications, such as bleeding. Small bowel ulcers can 
also lead to bleeding (hence the concept of obscure gastrointestinal bleeding3–6) and thus the patient’s desire to receive 
treatment would be understandable. 
In this study, we included patients taking proton-pump inhibitors who had small bowel ulcers at baseline. Previous 
literature3,6 has suggested that proton-pump inhibitors might aggravate the damaging effects of aspirin or NSAIDs on the 
small bowel mucosa. Multivariate regression analysis showed that the intake of these drugs did not influence the 
outcomes in our trial, but this result cannot be considered conclusive in view of the small sample size. 
Consistent with the results of our study, a previous trial13 reported that misoprostol is associated with nausea, 
vomiting, diarrhoea, and abdominal pain. The overall incidence of these adverse events was similar between the two 
treatment groups, but more patients in the misoprostol group reported severe symptoms than did patients in the placebo 
group. Notably, severe adverse events, which can be subjective, should not be confused with serious side-effects, which 
can lead to hospital treatment, disability, or death. No serious side-effects were noted in our study, and since none of the 
female patients were of childbearing age, there was no risk of abortion in the misoprostol group. The proportion of 
patients with adverse events in the placebo group (42%) and the misoprostol group (46%) was relatively high. Although 
some of these events were considered treatment-related, ulcerative small bowel disease itself is associated with many of 
the same side-effects as those our patients were prompted to record in their study diaries.  
We used the maximum recommended dose of misoprostol to maximise the number of patients with completely healed 
ulcers, thus it is possible that lower doses might still have efficacy and might be better tolerated, but this needs to be 
confirmed. Despite the adverse events, compliance to study treatment was not significantly different between the two 
groups. However, misoprostol should not be taken by women of childbearing age unless they use reliable contraceptive 
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methods because the drug can cause abortion. 
In conclusion, we have shown that misoprostol is more effective than placebo for the treatment of small bowel 
ulcers and erosions in patients using low-dose aspirin and NSAIDs who have obscure gastrointestinal bleeding. 
Thus, treatment with misoprostol would enable these patients to continue treatment with these drugs for their 
intended indications. However, the use of misoprostol must be balanced against the risk of side-effects. Also, it is 
difficult to anticipate the effectiveness of misoprostol in a population of patients with obscure gastrointestinal 
bleeding and transfusion-dependent anaemia. Efficacy and safety data for a population with more severe disease 
would be needed before the widespread use of misoprostol could be recommended. 
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Research in context 
 
Evidence before this study 
We searched PubMed from inception to Feb 2, 2018, for studies of any type published in English, regardless of date, using 
the search term “misoprostol for small bowel ulcers”. We found two publications that matched the search term. A previous 
preclinical trial found that gastroprotectant drugs prevented the exacerbation of enteric damage induced by non-steroidal 
anti-inflammatory drugs (NSAIDs) in rats. An open-label pilot study in human beings showed that erosive lesions of the 
small bowel in individuals taking enteric-coated aspirin healed in four of seven patients given misoprostol. Little is known 
about the efficacy of misoprostol for the treatment of small bowel ulcers associated with NSAIDs or aspirin in patients with 
obscure gastrointestinal bleeding. In view of the rising incidence of obscure gastrointestinal bleeding caused by aspirin and 
NSAIDs, which is now known to originate from the small bowel, misoprostol has received attention as a potential 
treatment for this condition. 
 
Added value of this study 
To the best of our knowledge, this is the largest study to date investigating the efficacy of misoprostol in patients taking 
NSAIDs or aspirin with obscure gastrointestinal bleeding. Our results show that misoprostol is more eff ective than 
placebo for the complete healing of small bowel ulcers in these patients after 8 weeks of treatment. No significant 
differences in haemoglobin concentrations were found between baseline and after 8 weeks of treatment in either group. 
Notably, the incidence of adverse events was relatively high in the misoprostol group. 
 
Implications of all the available evidence 
The results of this randomised trial indicate that misoprostol might represent a treatment option for patients with small 
bowel ulcers, which could be taken concurrently with NSAIDs or aspirin. However, misoprostol use can be associated with 
abdominal pain, nausea or vomiting, or diarrhoea in some patients. Future studies investigating the association between 
the treatment of small bowel ulcers and changes in haemoglobin concentrations in patients treated for longer than 8 
weeks, or in patients taking iron supplements, are warranted. We caution against giving misoprostol to women of 
childbearing age without the use of reliable contraceptive measures. 
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Table 1. Baseline characteristics. Data reported as number (%) or median [IQR]. 
Variable 
Misoprostol 
N=50 
Placebo 
N=52 
Age (years) at randomisation 68 [58, 71] 63 [57, 71] 
Gender 
 
Male 
Female 
30 (60%) 
20 (40%) 
24 (46.2%) 
28 (53.8%) 
Ethnicity 
 
White 
Mixed/ multiple ethnic groups 
Black/ African/ Caribbean 
50 (100%) 
0 (0%) 
0 (0%) 
50 (96.2%) 
1 (1.9%) 
1 (1.9%) 
Woman of child bearing age 0 (0%) 0 (0%) 
Iron deficiency anaemia 18 (36%) 22 (42.3%) 
Drop in haemoglobin > 20x103 mg/L within 3 months of  screening 1 (2%) 3 (5.8%) 
Positive faecal occult blood 31 (62%) 27 (52%) 
Other comorbid conditions 48 (96%) 50 (96.2%) 
Drug intake:   
Proton-Pump Inhibitors 34 (68%) 33 (63.5%) 
 NSAIDs 22 (44%) 20 (38.5%) 
 Aspirin 35 (70%) 34 (65.4%) 
Both NSAIDs and Aspirin 7 (14%) 2 (3.8%) 
Types of NSAIDs Taken:   
 Dicolfenac 2 (1.0%) 1 (0.5%) 
  Etodolac 3 (1.5%) 0 (0.0%) 
 Ibuprofen 1 (0.5%) 3 (1.4%) 
  Meloxicam 2 (1.0%) 6 (2.9%) 
  Nabumetone 1 (0.5%) 0 (0.0%) 
 Naproxen 14 (7.0%) 10 (4.8%) 
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Table 2: Primary* and secondary** outcomes, intention-to-treat analysis. Data reported as 
number (%) or median [IQR]. Treatment effect estimate reported as absolute percentage 
difference (PD), rate ratio (RR), or mean difference (MD) (Misoprostol – Placebo). P-values from 
Fisher’s Exact Tests, or Wilcoxon-Mann-Whitney tests 
Outcome 
Misoprostol 
N=50 
Placebo 
N=52 
 
Treatment 
Effect Estimate 
(95% CI) p-value 
Full healing of mucosal ulcers and erosions* 
 27 (54%) 9 (17.3%)  PD 36.7% (19.5%, 53.9%) 0.0002 
Full healing of mucosal ulcers* 
 34 (68%) 9 (17.3%)  PD 50.7% (34.2%, 67.2%) <0.0001 
Number of mucosal ulcers** 
Baseline 3 [2, 4] 2 [2, 4]      
8 weeks 0 [0, 1] 3 [1.5, 4]  RR 0.22 (0.13, 0.35) <0.0001 
Change -2 [-4, -1] 0.5 [-1, 1]     <0.0001 
Full healing of mucosal erosions* 
 28 (56%) 11 (21.2%)  PD 34.8% (17.2%, 52.5%) 0.0005 
Number of mucosal erosions** 
Baseline 4 [3, 6] 4 [3, 6]      
8 weeks 0 [0, 3] 5 [2, 6.5]  RR 0.36 (0.23, 0.56) <0.0001 
Change at 8 weeks -3 [-4, 0] 1 [-2, 2]     <0.0001 
Haemoglobin** 
Baseline 
N=49 
136 [117, 145] 
N=52 
133 [122, 146.5] 
     
4 weeks 
N=42 
133 [119, 147] 
N=50 
132 [120, 147] 
 MD -0.14 (-3.90, 3.62) 0.95 
Change at 4 weeks -5 [-7, 1] -4.5 [-9, 2]     0.80 
8 weeks 
N=39 
136 [121, 145] 
N=50 
136 [121, 145] 
 MD 1.20 (-1.84, 4.24) 0.82 
Change at 8 weeks 0 [-3, 4] -3 [-5, 4]     0.18 
 
Note: subjects without final video capsule endoscopy data are assumed to have the same number 
of mucosal ulcers and erosions as at baseline, and are counted as not healed, in these analyses 
(web appendix page1 for complete case analysis and page 2 for per-protocol analysis results). The 
haemoglobin analysis uses complete data only and was derived from normal linear regression. 
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Table 3: Adverse Events. Data reported as number (%). 
  
Misoprostol 
N=50 
Placebo 
N=52 
Number of Adverse Events 65 57 
Patients with at least one Adverse Event 23 (46%) 22 (42%) 
Number of Serious Adverse Events 0 0 
Patients with at least one Serious Adverse Event 0 (0%) 0 (0%) 
Adverse Event Type N Events Patients N Events Patients 
 
Abdominal Pain 
Diarrhoea 
Nausea/vomiting 
Other: 
14  
13  
13  
25  
10 (20%) 
11 (22%) 
9 (18%) 
13 (26%) 
14  
8  
11 
24 
13 (25%) 
6 (12%) 
7 (14%) 
15 (29%) 
  
Bloating 
Constipation 
Difficulty Swallowing  
Heartburn 
Regurgitation 
7  
1  
3  
10  
4 
3 (6%) 
1 (2%) 
2 (4%) 
7 (14%) 
3 (6%) 
6  
2 
1  
14  
1 
4 (8%) 
2 (4%) 
1 (2%) 
12 (23%) 
1 (2%) 
Adverse Event Severity*     
 
Mild 
Moderate 
Severe 
34  
25  
6 
16 (32%) 
16 (32%) 
4 (8%) 
40  
16  
0 
17(33%) 
10 (19%) 
0 (0%) 
* p=0.017 vs. placebo, Fisher’s Exact Test for Number of Events. Number of patients for each 
severity level Fisher’s Exact tests p-values are not significant 
 
 
 
 
 
